A Time-Cost Augmented Economic Evaluation of Oral Deferasirox versus Infusional Dereroxmine for Patients with Iron Overload in South Korea
Article first published online: 6 NOV 2009
© 2009, International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
Value in Health
Special Issue: Pharmacoeconomics and Outcomes Research in Asia
Volume 12, Issue Supplement s3, pages S78–S81, November/December 2009
How to Cite
Kim, J. and Kim, Y. (2009), A Time-Cost Augmented Economic Evaluation of Oral Deferasirox versus Infusional Dereroxmine for Patients with Iron Overload in South Korea. Value in Health, 12: S78–S81. doi: 10.1111/j.1524-4733.2009.00633.x
- Issue published online: 6 NOV 2009
- Article first published online: 6 NOV 2009
Vol. 13, Issue 2, 336, Article first published online: 17 FEB 2010
- cost-effectiveness analysis;
- cost-utility analysis;
- iron chelating agents
Objectives: This study aims to conduct an economic evaluation of oral deferasirox (DSX) compared with infusional deferoxamine (DFO) in patients with transfusional iron overload.
Methods: Depending on the methods for measuring time-cost and convenience associated with the mode of administration, either cost-utility analysis or cost-effectiveness analysis was undertaken. The difference in compliance rate between DSX and DFO was applied.
Results: Although the drug cost of DSX was US$124,070 higher than that of DFO (US$96,039 vs. US$220,199), all other costs were lower in patients with DSX than in patients with DFO. In the cost-utility analysis, DSX resulted in US$3197 savings with a gain of 2.63 quality-adjusted life-years per patient. The result of the cost-effectiveness analysis also showed that DSX dominated DFO.
Conclusions: With a considerable improvement in convenience and injection time rather than efficacy, DSX is considered as a dominant therapy for patients with iron overload.